Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells 958 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the sale, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.45, for a total value of $2,286,779.95.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $43.45 on Thursday. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60. The firm has a market cap of $2.25 billion, a P/E ratio of -35.61 and a beta of 3.57. The business’s 50 day moving average price is $43.81 and its 200-day moving average price is $44.67.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The company’s revenue for the quarter was up 709.1% on a year-over-year basis. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research report on Monday, August 19th. Stifel Nicolaus began coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Scotiabank decreased their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Finally, Wedbush reissued an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $5,715,000. Blue Owl Capital Holdings LP bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $1,676,000. The Manufacturers Life Insurance Company grew its stake in Janux Therapeutics by 234.7% in the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock worth $1,007,000 after purchasing an additional 16,864 shares during the period. AQR Capital Management LLC bought a new position in Janux Therapeutics in the second quarter worth $215,000. Finally, Samlyn Capital LLC raised its holdings in Janux Therapeutics by 9.6% in the second quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock worth $13,602,000 after purchasing an additional 28,312 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.